Try Fund Library Premium
Free with a 30 day trial!
Gain access to
- Unlimited Watchlists
- Advanced Search Filtering
- Fund Comparisons
- Portfolio Scenarios
- Customizable PDF Reports
- Portfolio Rebalancer new
TD Health Sciences Fund - Investor Series
Health Care Equity
Click for more information on Fundata’s FundGrade
FundGrade B
Click for more information on Fundata’s FundGrade.
Click for more information on Fundata’s ESG Grade
Fundata ESG Grade A
Click for more information on Fundata’s ESG Grade.
FundGrade A+® Rating Recipient
2012
Click for more information on Fundata’s FundGrade
|
NAVPS (05-13-2026) |
$125.22 |
|---|---|
| Change |
$1.06
(0.85%)
|
As at April 30, 2026
As at April 30, 2026
As at April 30, 2026
Loading......
Legend
Compare Options
Fund Returns
Inception Return (October 31, 1996): 9.83%
| Row Heading | Return | Annualized Return | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 Mth | 3 Mth | 6 Mth | YTD | 1 Yr | 2 Yr | 3 Yr | 4 Yr | 5 Yr | 6 Yr | 7 Yr | 8 Yr | 9 Yr | 10 Yr | |
| Fund | -1.01% | -4.55% | -2.21% | -6.34% | 8.79% | 2.84% | 3.26% | 4.94% | 2.20% | 4.74% | 6.46% | 7.18% | 6.95% | 8.36% |
| Benchmark | -2.20% | -5.11% | -0.92% | -4.87% | 5.78% | 3.80% | 4.47% | 5.87% | 5.46% | 5.98% | 7.70% | 8.37% | 7.92% | 8.80% |
| Category Average | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Category Rank | 12 / 53 | 14 / 51 | 28 / 51 | 22 / 51 | 11 / 51 | 21 / 49 | 16 / 43 | 13 / 41 | 20 / 39 | 15 / 36 | 16 / 35 | 9 / 32 | 7 / 29 | 5 / 29 |
| Quartile Ranking | 1 | 2 | 3 | 2 | 1 | 2 | 2 | 2 | 3 | 2 | 2 | 2 | 1 | 1 |
Monthly Return
| Return % | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Jan | Feb | Mar | Apr |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Fund | -6.83% | 2.95% | 0.30% | 3.07% | 3.35% | 8.55% | 8.43% | -3.71% | -1.88% | 0.64% | -4.19% | -1.01% |
| Benchmark | -3.48% | 0.91% | -0.60% | 4.16% | 2.38% | 3.42% | 7.21% | -2.85% | 0.25% | 3.41% | -6.17% | -2.20% |
Best Monthly Return Since Inception
24.29% (June 2000)
Worst Monthly Return Since Inception
-17.38% (March 2000)
Calendar Return (%)
| Return % | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Fund | -15.15% | 17.32% | 7.57% | 20.38% | 24.11% | 9.45% | -7.96% | -0.96% | 8.12% | 10.49% |
| Benchmark | -8.68% | 14.01% | 11.82% | 17.06% | 13.59% | 15.28% | -1.72% | 1.42% | 9.95% | 9.64% |
| Category Average | - | - | - | - | - | - | - | - | - | - |
| Quartile Ranking | 3 | 1 | 2 | 1 | 1 | 4 | 4 | 4 | 2 | 2 |
| Category Rank | 19/ 29 | 5/ 29 | 14/ 32 | 8/ 34 | 6/ 35 | 29/ 38 | 33/ 40 | 31/ 41 | 24/ 48 | 19/ 50 |
Best Calendar Return (Last 10 years)
24.11% (2020)
Worst Calendar Return (Last 10 years)
-15.15% (2016)
Asset Allocation
| Name | Percent |
|---|---|
| US Equity | 92.33 |
| International Equity | 6.46 |
| Cash and Equivalents | 0.87 |
| Foreign Corporate Bonds | 0.31 |
| Canadian Equity | 0.03 |
Sector Allocation
| Name | Percent |
|---|---|
| Healthcare | 91.25 |
| Consumer Services | 0.96 |
| Cash and Cash Equivalent | 0.87 |
| Fixed Income | 0.31 |
| Financial Services | 0.02 |
| Other | 6.59 |
Geographic Allocation
| Name | Percent |
|---|---|
| North America | 93.55 |
| Europe | 4.76 |
| Asia | 0.85 |
| Latin America | 0.83 |
| Africa and Middle East | 0.04 |
Top Holdings
| Name | Percent |
|---|---|
| Eli Lilly and Co | 10.35 |
| Johnson & Johnson | 5.98 |
| UnitedHealth Group Inc | 5.75 |
| Abbvie Inc | 5.07 |
| Thermo Fisher Scientific Inc | 3.48 |
| Merck & Co Inc | 3.43 |
| Intuitive Surgical Inc | 3.20 |
| Gilead Sciences Inc | 2.46 |
| Vertex Pharmaceuticals Inc | 2.33 |
| Stryker Corp | 2.15 |
Equity Style
Fixed Income Style
Risk vs Return (3 Yr)
TD Health Sciences Fund - Investor Series
Median
Other - Health Care Equity
3 Yr Annualized
| Standard Deviation | 13.37% | 14.01% | 14.48% |
|---|---|---|---|
| Beta | 1.06 | 1.07 | 1.10 |
| Alpha | -0.01 | -0.03 | -0.01 |
| Rsquared | 0.81% | 0.81% | 0.79% |
| Sharpe | 0.03 | 0.02 | 0.50 |
| Sortino | 0.12 | 0.02 | 0.67 |
| Treynor | 0.00 | 0.00 | 0.07 |
| Tax Efficiency | 100.00% | 100.00% | 100.00% |
| Volatility |
|
|
|
Risk Rating
Annualized Key Ratio Period Comparison
| Key Ratio | 1 Yr | 3 Yr | 5 Yr | 10 Yr |
|---|---|---|---|---|
| Standard Deviation | 16.48% | 13.37% | 14.01% | 14.48% |
| Beta | 1.08 | 1.06 | 1.07 | 1.10 |
| Alpha | 0.03 | -0.01 | -0.03 | -0.01 |
| Rsquared | 0.75% | 0.81% | 0.81% | 0.79% |
| Sharpe | 0.44 | 0.03 | 0.02 | 0.50 |
| Sortino | 0.70 | 0.12 | 0.02 | 0.67 |
| Treynor | 0.07 | 0.00 | 0.00 | 0.07 |
| Tax Efficiency | 100.00% | 100.00% | 100.00% | 100.00% |
Fundata ESG Metrics
Fundata ESG Score
The E, S, and G scores are averaged for each security in the portfolio, to arrive at an ESG score for each security. We take the portfolio weighted average of the ESG scores for each fund and rank them against their peers to arrive at the Fundata ESG Score from 0-100.
Fundata E Score
Three scores under the Environment bucket are averaged to yield the Fundata Environment Score for each fund from 0-100: (1) Pollution Prevention, (2) Environmental Transparency, (3) Resource Efficiency.
Fundata S Score
Six scores under the Social bucket are averaged to yield the Fundata Social Score for each fund from 0-100. (1) Compensation and Satisfaction, (2) Diversity and Rights, (3) Education and Work Conditions, (4) Community and Charity, (5) Human Rights, (6) Sustainability Integration.
Fundata G Score
Three scores under the governance bucket are averaged to yield the Fundata Governance Score for each fund from 0-100: (1) Board Effectiveness, (2) Management Ethics, (3) Disclosure and Accountability.
Powered by OWL Analytics. For more information, please contact Fundata Canada.
Fund Details
| Start Date | October 31, 1996 |
|---|---|
| Instrument Type | Mutual Fund |
| Share Class | Commission Based Advice |
| Legal Status | Trust |
| Sales Status | Open |
| Currency | CAD |
| Distribution Frequency | Annual |
| Assets ($mil) | $1,183 |
Fund Codes
| FundServ Code | Load Code | Sales Status |
|---|---|---|
| TDB976 |
Investment Objectives
The fundamental investment objective of the Fund is to achieve long-term capital appreciation by investing primarily in equity securities of companies located in the United States and other countries, that are engaged in the research, development, production, or distribution of products or services related to health care, medicine, or the life sciences.
Investment Strategy
The sub-adviser seeks to achieve the fundamental investment objective of the Fund by investing at least 65% of the Fund’s total assets in common stocks of companies in the research, development, production, or distribution of products or services related to health care, medicine, or the life sciences. The sub-adviser divides the health sciences sector into four main areas: pharmaceuticals, health care services, products and devices, and biotechnology firms.
Portfolio Management
| Portfolio Manager |
TD Asset Management Inc. |
|---|---|
| Sub-Advisor |
T. Rowe Price Associates, Inc.
|
Management and Organization
| Fund Manager |
TD Asset Management Inc. |
|---|---|
| Custodian |
CIBC Mellon Trust Company |
| Registrar |
The Toronto-Dominion Bank |
| Distributor |
TD Investment Services Inc |
Investment Minimums
| RSP Eligible | Yes |
|---|---|
| PAC Allowed | Yes |
| PAC Initial Investment | - |
| PAC Subsequent | - |
| SWP Allowed | Yes |
| SWP Min Balance | 10,000 |
| SWP Min Withdrawal | 100 |
Fees
| MER | 2.72% |
|---|---|
| Management Fee | 2.25% |
| Load | No Load |
| FE Max | - |
| DSC Max | - |
| Trailer Fee Max (FE) | - |
| Trailer Fee Max (DSC) | - |
| Trailer Fee Max (NL) | 1.00% |
| Trailer Fee Max (LL) | - |
Try Fund Library Premium
Free with a 30 day trial!
Gain access to
- Unlimited Watchlists
- Advanced Search Filtering
- Fund Comparisons
- Portfolio Scenarios
- Customizable PDF Reports
- Portfolio Rebalancer new
